3 completed, 3 unknown, 1 recruiting. 7 Phase 2, 2 Phase 3, 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 3, Unknown 3, Recruiting 1 |
| Phase 3 | 2 | Unknown 2 |
| Phase 1 | 1 | Completed 1 |
Follow nafamostat: new trials by email Literature Review of nafamostat trials Research Report on nafamostat
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Comparison of Anticoagulant Effects of Different Doses of Nafamostat in Continuous Renal Replacement Therapy (CRRT) in the Intensive Care Unit (ICU) Nafamostat Low-Dose Group, Nafamostat High-Dose Group - Continuous Renal Replacement Therapy (CRRT) | Phase 2 | Recruiting | Zhujiang Hospital | 92 | 2026-04-07 | 2026-04-14 |
| Efficacy and Safety of Nafamostat Mesylate for VV-ECMO Anticoagulation Nafamostat Mesylate, Unfractionated Heparin - Critical Illness, Anticoagulation | Phase 2 | Unknown | Xiaobo Yang, MD | 40 | 2022-12-20 | 2023-02-15 |
| Efficacy of Nafamostat in Covid-19 Patients (RACONA Study) Nafamostat Mesilate, Placebo - COVID19 | Phase 2 / Phase 3 | Unknown | University Hospital Padova | 256 | 2021-06-04 | 2023-11-01 |
| A Study Evaluating the Efficacy and Safety of CKD-314 in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia Nafamostat Mesilate - COVID-19 | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 13 | 2020-12-21 | 2021-08-13 |
| A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia Nafamostat Mesilate - COVID-19 | Phase 2 | Completed | Chong Kun Dang Pharmaceutical | 104 | 2020-09-25 | 2021-02-02 |
| DEFINE - Evaluating Therapies for COVID-19 Nafamostat Mesilate, TD139, Standard care - COVID-19 | Phase 1 / Phase 2 | Completed | University of Edinburgh | 71 | 2020-07-03 | 2025-08-07 |
| Clinical Efficacy of Nafamostat Mesylate for COVID-19 Pneumonia Nafamostat Mesylate - Corona Virus Infection, COVID-19 | Phase 2 / Phase 3 | Unknown | Gyeongsang National University Hospital | 84 | 2020-06-10 | 2020-06-09 |
COVID-19 (5) · Coronavirus Infections (2) · Critical Illness (1) · Pneumonia (1)
Chong Kun Dang Pharmaceutical (2) · Gyeongsang National University Hospital (1) · University Hospital Padova (1) · University of Edinburgh (1) · Xiaobo Yang, MD (1) · Zhujiang Hospital (1)
China (2) · Italy (1) · Russia (1) · South Korea (1) · United Kingdom (1)
Dongho Kim, MD (1) · Gian Paolo Rossi, Prof. (1) · Kev Dhaliwal (1) · Zhanguo Liu, M.D.PhD (1)
PMID 32142651, PMID 11594901, PMID 25822153, PMID 27550352, PMID 30536180, PMID 32171076, PMID 32187464, PMID 32312781, PMID 33502773, PMID 34473343, PMID 34723164, PMID 34814935, PMID 35152152, PMID 35244208, PMID 35972987